Warby Parker (WRBY) Stock Forecast, Price Target & Predictions
WRBY Stock Forecast
Warby Parker stock forecast is as follows: an average price target of $18.00 (represents a -28.51% downside from WRBY’s last price of $25.18) and a rating consensus of 'Buy', based on 14 wall street analysts offering a 1-year stock forecast.
WRBY Price Target
The average price target for Warby Parker (WRBY) is $18.00 based on 1-year price targets from 14 Wall Street analysts in the past 3 months, with a price target range of $22.00 to $15.00. This represents a potential -28.51% downside from WRBY's last price of $25.18.
WRBY Analyst Ratings
According to 14 Wall Street analysts, Warby Parker's rating consensus is 'Buy'. The analyst rating breakdown for WRBY stock is 0 'Strong Buy' (0.00%), 9 'Buy' (64.29%), 5 'Hold' (35.71%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Warby Parker Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 08, 2024 | Anna Andreeva | Piper Sandler | $22.00 | $19.51 | 12.76% | -12.63% |
| Oct 29, 2024 | Paul Lejuez | Citigroup | $15.00 | $17.21 | -12.84% | -40.43% |
| Oct 21, 2024 | Brooke Roach | Goldman Sachs | $18.00 | $16.55 | 8.76% | -28.51% |
| Sep 27, 2024 | Ana Garcia | CFRA | $20.00 | $16.03 | 24.77% | -20.57% |
| Aug 23, 2024 | Nicholas Jones | JMP Securities | $20.00 | $13.86 | 44.30% | -20.57% |
| Aug 22, 2024 | Anna Andreeva | Piper Sandler | $18.00 | $13.86 | 29.87% | -28.51% |
| Aug 08, 2024 | Jim Duffy | Stifel Nicolaus | $15.00 | $14.04 | 6.84% | -40.43% |
| Jul 10, 2024 | Anthony Chukumba | Loop Capital Markets | $16.00 | $15.64 | 2.30% | -36.46% |
| May 10, 2024 | Anthony Chukumba | Loop Capital Markets | $15.00 | $15.03 | -0.20% | -40.43% |
| May 10, 2024 | Mark Carden | UBS | $15.00 | $15.33 | -2.15% | -40.43% |
| May 09, 2024 | Mark Mahaney | Evercore ISI | $19.00 | $14.63 | 29.89% | -24.54% |
| Dec 15, 2022 | Wolfe Research | $20.00 | $15.54 | 28.70% | -20.57% | |
| Nov 14, 2022 | Morgan Stanley | $11.00 | $16.52 | -33.41% | -56.31% | |
| Nov 11, 2022 | Citigroup | $26.00 | $16.01 | 62.40% | 3.26% | |
| Jul 22, 2022 | Edward Yruma | Piper Sandler | $20.00 | $12.19 | 64.07% | -20.57% |
| May 17, 2022 | Mark Mahaney | Evercore ISI | $23.00 | $17.47 | 31.65% | -8.66% |
The latest Warby Parker stock forecast, released on Nov 08, 2024 by Anna Andreeva from Piper Sandler, set a price target of $22.00, which represents a 12.76% increase from the stock price at the time of the forecast ($19.51), and a -12.63% decrease from WRBY last price ($25.18).
Warby Parker Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 4 | 11 |
| Avg Price Target | - | $18.75 | $17.55 |
| Last Closing Price | $25.18 | $25.18 | $25.18 |
| Upside/Downside | -100.00% | -25.54% | -30.30% |
In the current month, the average price target of Warby Parker stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Warby Parker's last price of $25.18. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 08, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Nov 07, 2024 | William Blair | Outperform | Upgrade | |
| Oct 29, 2024 | Citigroup | Neutral | Neutral | Hold |
| Oct 21, 2024 | Telsey Advisory | Market Outperform | Market Outperform | Hold |
| Oct 21, 2024 | Piper Sandler | Underperform | Underperform | Hold |
| Oct 21, 2024 | Goldman Sachs | Buy | Upgrade | |
| Oct 03, 2024 | Loop Capital Markets | Hold | Hold | Hold |
| Sep 27, 2024 | CFRA | Buy | Buy | Hold |
| Aug 23, 2024 | Piper Sandler | Underperform | Underperform | Hold |
| Aug 23, 2024 | Telsey Advisory | Market Outperform | Market Outperform | Hold |
| Aug 22, 2024 | JMP Securities | Outperform | Upgrade | |
| Aug 01, 2024 | Telsey Advisory | Underperform | Underperform | Hold |
| Aug 01, 2024 | UBS | Equal-Weight | Equal-Weight | Hold |
| Jul 10, 2024 | UBS | Equal-Weight | Equal-Weight | Hold |
| Jul 10, 2024 | Telsey Advisory | Underperform | Underperform | Hold |
| Jul 10, 2024 | Loop Capital Markets | Hold | Hold | Hold |
| May 10, 2024 | UBS | Equal-Weight | Equal-Weight | Hold |
| May 10, 2024 | Telsey Advisory | Underperform | Underperform | Hold |
| May 10, 2024 | Cowen & Co. | Buy | Buy | Hold |
| May 10, 2024 | Loop Capital Markets | Hold | Hold | Hold |
| May 10, 2024 | Citigroup | Neutral | Neutral | Hold |
| May 10, 2024 | UBS | Neutral | Neutral | Hold |
| May 09, 2024 | Evercore ISI | Outperform | Outperform | Hold |
| Oct 03, 2023 | Evercore ISI | Hold | Outperform | Upgrade |
| Feb 07, 2023 | BTIG | Neutral | Initialise | |
| Dec 15, 2022 | Wolfe Research | Outperform | Initialise | |
| Nov 14, 2022 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| Nov 11, 2022 | Citigroup | Buy | Buy | Hold |
| May 17, 2022 | Evercore ISI | Hold | Hold | Hold |
| May 17, 2022 | CFRA | Buy | Buy | Hold |
Warby Parker's last stock rating was published by Piper Sandler on Nov 08, 2024. The company gave WRBY a "Overweight" rating, the same as its previous rate.
Warby Parker Financial Forecast
Warby Parker Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $169.85M | $166.09M | $171.97M | $146.49M | $148.78M | $149.62M | $153.22M | $132.89M | $137.37M |
| Avg Forecast | $237.06M | $241.43M | $235.38M | $247.81M | $213.32M | $219.12M | $214.10M | $224.55M | $186.79M | $190.14M | $187.03M | $196.41M | $160.85M | $164.70M | $162.56M | $166.75M | $142.56M | $144.68M | $149.50M | $154.08M | $133.35M | $133.03M |
| High Forecast | $239.92M | $244.35M | $238.22M | $250.80M | $215.89M | $221.77M | $216.69M | $225.06M | $187.75M | $190.27M | $187.03M | $196.41M | $164.29M | $164.71M | $164.52M | $168.76M | $144.29M | $144.68M | $149.50M | $154.08M | $133.35M | $133.03M |
| Low Forecast | $235.01M | $239.35M | $233.35M | $245.67M | $211.48M | $217.23M | $212.26M | $224.04M | $185.85M | $190.01M | $187.03M | $196.41M | $159.15M | $164.69M | $161.16M | $165.31M | $141.33M | $144.68M | $149.50M | $154.08M | $133.35M | $133.03M |
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 9 | 4 | 7 | 4 | 9 | 4 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.03% | 1.02% | 1.03% | 1.03% | 1.03% | 1.00% | 0.99% | 1.00% | 1.03% |
Warby Parker's average Quarter revenue forecast for Dec 23 based on 9 analysts is $160.85M, with a low forecast of $159.15M, and a high forecast of $164.29M. WRBY's average Quarter revenue forecast represents a -5.30% decrease compared to the company's last Quarter revenue of $169.85M (Sep 23).
Warby Parker EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 9 | 4 | 7 | 4 | 9 | 4 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-19.77M | $-18.23M | $-3.29M | $-21.71M | $-15.74M | $-24.20M | $-26.60M | $-39.24M | $-86.48M |
| Avg Forecast | $-21.83M | $-22.24M | $-21.68M | $-22.83M | $-19.65M | $-20.18M | $-19.72M | $-20.68M | $-17.21M | $-17.51M | $-17.23M | $-18.09M | $-14.82M | $-15.17M | $-14.97M | $-15.36M | $-13.13M | $-13.53M | $-13.99M | $-14.41M | $-12.47M | $-12.44M |
| High Forecast | $-21.65M | $-22.05M | $-21.49M | $-22.63M | $-19.48M | $-20.01M | $-19.55M | $-20.64M | $-17.12M | $-17.50M | $-17.23M | $-18.09M | $-14.66M | $-15.17M | $-14.84M | $-15.23M | $-13.02M | $-13.53M | $-13.99M | $-14.41M | $-12.47M | $-12.44M |
| Low Forecast | $-22.10M | $-22.51M | $-21.94M | $-23.10M | $-19.89M | $-20.43M | $-19.96M | $-20.73M | $-17.29M | $-17.53M | $-17.23M | $-18.09M | $-15.13M | $-15.17M | $-15.15M | $-15.54M | $-13.29M | $-13.53M | $-13.99M | $-14.41M | $-12.47M | $-12.44M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.30% | 1.22% | 0.21% | 1.65% | 1.16% | 1.73% | 1.85% | 3.15% | 6.95% |
undefined analysts predict WRBY's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Warby Parker's previous annual EBITDA (undefined) of $NaN.
Warby Parker Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 9 | 4 | 7 | 4 | 9 | 4 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-17.41M | $-15.93M | $-10.81M | $-20.25M | $-23.84M | $-32.17M | $-34.13M | $-45.90M | $-91.07M |
| Avg Forecast | $7.57M | $4.67M | $7.01M | $9.70M | $6.39M | $7.37M | $9.73M | $12.82M | $3.26M | $6.33M | $6.25M | $8.21M | $807.52K | $941.46K | $2.78M | $5.44M | $-86.31K | $3.19M | $-2.53M | $522.26K | $-10.82M | $-62.79M |
| High Forecast | $7.69M | $4.75M | $7.12M | $9.85M | $6.49M | $7.48M | $9.88M | $13.03M | $6.51M | $6.47M | $6.27M | $8.21M | $826.86K | $956.25K | $2.83M | $5.52M | $-85.34K | $3.19M | $-2.53M | $522.26K | $-10.82M | $-62.79M |
| Low Forecast | $7.48M | $4.62M | $6.93M | $9.59M | $6.32M | $7.29M | $9.62M | $12.68M | $1.09M | $6.19M | $6.23M | $8.20M | $788.18K | $930.90K | $2.75M | $5.37M | $-87.67K | $3.19M | $-2.53M | $522.26K | $-10.82M | $-62.79M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -18.50% | -5.72% | -1.99% | 234.63% | -7.47% | 12.69% | -65.36% | 4.24% | 1.45% |
Warby Parker's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. WRBY's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Warby Parker SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 9 | 4 | 7 | 4 | 9 | 4 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $112.50M | $108.86M | $107.22M | $102.36M | $108.09M | $118.43M | $123.39M | $122.15M | $171.64M |
| Avg Forecast | $170.65M | $173.79M | $169.44M | $178.39M | $153.56M | $157.73M | $154.12M | $161.64M | $134.46M | $136.87M | $134.63M | $141.38M | $115.79M | $118.56M | $117.02M | $120.03M | $102.63M | $103.61M | $107.07M | $110.35M | $95.50M | $95.27M |
| High Forecast | $172.71M | $175.89M | $171.48M | $180.54M | $155.41M | $159.64M | $155.98M | $162.01M | $135.15M | $136.96M | $134.63M | $141.38M | $118.27M | $118.57M | $118.43M | $121.48M | $103.87M | $103.61M | $107.07M | $110.35M | $95.50M | $95.27M |
| Low Forecast | $169.18M | $172.29M | $167.97M | $176.85M | $152.23M | $156.37M | $152.79M | $161.28M | $133.79M | $136.78M | $134.63M | $141.38M | $114.56M | $118.55M | $116.01M | $119.00M | $101.74M | $103.61M | $107.07M | $110.35M | $95.50M | $95.27M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.95% | 0.93% | 0.89% | 1.00% | 1.04% | 1.11% | 1.12% | 1.28% | 1.80% |
Warby Parker's average Quarter SG&A projection for Dec 23 is $115.79M, based on 9 Wall Street analysts, with a range of $114.56M to $118.27M. The forecast indicates a 2.93% rise compared to WRBY last annual SG&A of $112.50M (Sep 23).
Warby Parker EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 9 | 4 | 7 | 4 | 9 | 4 | 6 | 4 | 3 | 7 | 4 | 3 | 4 | 7 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.15 | $-0.14 | $-0.09 | $-0.18 | $-0.21 | $-0.28 | $-0.30 | $-0.41 | $-1.45 |
| Avg Forecast | $0.06 | $0.04 | $0.06 | $0.08 | $0.05 | $0.06 | $0.08 | $0.11 | $0.03 | $0.05 | $0.05 | $0.07 | $0.01 | $0.01 | $0.02 | $0.04 | $-0.00 | $0.03 | $-0.02 | - | $-0.09 | $-0.52 |
| High Forecast | $0.06 | $0.04 | $0.06 | $0.08 | $0.05 | $0.06 | $0.08 | $0.11 | $0.05 | $0.05 | $0.05 | $0.07 | $0.01 | $0.01 | $0.02 | $0.05 | $-0.00 | $0.03 | $-0.02 | - | $-0.09 | $-0.52 |
| Low Forecast | $0.06 | $0.04 | $0.06 | $0.08 | $0.05 | $0.06 | $0.08 | $0.10 | $0.01 | $0.05 | $0.05 | $0.07 | $0.01 | $0.01 | $0.02 | $0.04 | $-0.00 | $0.03 | $-0.02 | - | $-0.09 | $-0.52 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -19.26% | -6.08% | -2.07% | 252.10% | -7.90% | 13.27% | -68.98% | 4.55% | 2.77% |
According to undefined Wall Street analysts, Warby Parker's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to WRBY previous annual EPS of $NaN (undefined).
Warby Parker Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| TFX | Teleflex | $178.28 | $254.50 | 42.75% | Buy |
| ANGO | AngioDynamics | $9.26 | $13.00 | 40.39% | Buy |
| HAE | Haemonetics | $82.07 | $107.00 | 30.38% | Buy |
| BDX | Becton, Dickinson and Company | $225.64 | $278.75 | 23.54% | Buy |
| ATR | AptarGroup | $163.09 | $200.00 | 22.63% | Buy |
| COO | Cooper Companies | $94.49 | $115.00 | 21.71% | Buy |
| ALC | Alcon | $85.54 | $104.00 | 21.58% | Buy |
| ICUI | ICU Medical | $157.17 | $190.50 | 21.21% | Buy |
| WST | West Pharmaceutical Services | $334.26 | $393.00 | 17.57% | Buy |
| BLFS | BioLife Solutions | $26.87 | $30.00 | 11.65% | Buy |
| MMSI | Merit Medical Systems | $99.00 | $108.83 | 9.93% | Buy |
| LMAT | LeMaitre Vascular | $90.93 | $98.00 | 7.78% | Buy |
| NVST | Envista | $19.24 | $20.29 | 5.46% | Hold |
| HOLX | Hologic | $72.26 | $74.20 | 2.68% | Buy |
| RMD | ResMed | $242.62 | $233.50 | -3.76% | Hold |
| KRMD | KORU Medical Systems | $4.12 | $3.25 | -21.12% | Buy |
| WRBY | Warby Parker | $24.29 | $18.00 | -25.90% | Buy |